Antimalarial drug discovery — approaches and progress towards new medicines

Malaria elimination has recently been reinstated as a global health priority but current therapies seem to be insufficient for the task. Elimination efforts require new drug classes that alleviate symptoms, prevent transmission and provide a radical cure. To develop these next-generation medicines, public–private partnerships are funding innovative approaches to identify compounds that target multiple parasite species at multiple stages of the parasite life cycle. In this Review, we discuss the cell-, chemistry- and target-based approaches used to discover new drug candidates that are currently in clinical trials or undergoing preclinical testing.

[1]  P. Rathod,et al.  High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.

[2]  S. Abdulla,et al.  Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children , 2009, Malaria Journal.

[3]  C. Siethoff,et al.  First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials , 2012, British journal of clinical pharmacology.

[4]  B. K. Park,et al.  Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. , 2010, Angewandte Chemie.

[5]  R. Sinden,et al.  Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay. , 2012, International journal for parasitology.

[6]  E. Winzeler,et al.  Genetic Analysis of Primaquine Tolerance in a Patient with Relapsing Vivax Malaria , 2013, Emerging infectious diseases.

[7]  T. Wells Natural products as starting points for future anti-malarial therapies: going back to our roots? , 2011, Malaria Journal.

[8]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[9]  Xiang-Lei Yang,et al.  ATP-Directed Capture of Bioactive Herbal-Based Medicine on Human tRNA Synthetase , 2012, Nature.

[10]  David M. Shackleford,et al.  Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. , 2011, Journal of medicinal chemistry.

[11]  K. Williamson,et al.  A High-Throughput Screen Targeting Malaria Transmission Stages Opens New Avenues for Drug Development , 2011, The Journal of infectious diseases.

[12]  C. Biot,et al.  Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action , 2008, Molecules.

[13]  Joana C. Silva,et al.  Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia , 2012, Proceedings of the National Academy of Sciences.

[14]  Yingyao Zhou,et al.  Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery , 2011, Science.

[15]  K. Cimanga,et al.  Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 1: a clinical phase IIA trial. , 2012, Planta medica.

[16]  A. Vaughan,et al.  Malaria parasite development in the mosquito and infection of the mammalian host. , 2009, Annual review of microbiology.

[17]  C. Holland,et al.  Ascaris co-infection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children , 2013, Malaria Journal.

[18]  M. Enserink If artemisinin drugs fail, what's plan B? , 2010, Science.

[19]  X. Su,et al.  A Class of Tricyclic Compounds Blocking Malaria Parasite Oocyst Development and Transmission , 2012, Antimicrobial Agents and Chemotherapy.

[20]  Silvia Parapini,et al.  A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. , 2013, The Journal of antimicrobial chemotherapy.

[21]  L. H. Schmidt,et al.  Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. , 1977, The American journal of tropical medicine and hygiene.

[22]  S. Hoffman,et al.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.

[23]  N. White Cardiotoxicity of antimalarial drugs. , 2007, The Lancet. Infectious diseases.

[24]  V. A. Stewart,et al.  Immune mechanisms in malaria: new insights in vaccine development , 2013, Nature Medicine.

[25]  E. McGraw,et al.  Beyond insecticides: new thinking on an ancient problem , 2013, Nature Reviews Microbiology.

[26]  Danny W. Wilson,et al.  Cell-Cell Communication between Malaria-Infected Red Blood Cells via Exosome-like Vesicles , 2013, Cell.

[27]  S. Apers,et al.  Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract. , 2010, Journal of ethnopharmacology.

[28]  S. Meshnick,et al.  The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. , 1994, Experimental parasitology.

[29]  C. Fang,et al.  Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  E. Winzeler,et al.  Validation of isoleucine utilization targets in Plasmodium falciparum , 2011, Proceedings of the National Academy of Sciences.

[31]  Serge Batalov,et al.  Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum , 2009, Genome Biology.

[32]  M. Toner,et al.  Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. , 2013, Cell host & microbe.

[33]  L. Rénia,et al.  A pre-emptive strike against malaria's stealthy hepatic forms , 2009, Nature Reviews Drug Discovery.

[34]  L. Shultz,et al.  Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.

[35]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[36]  G. van Gemert,et al.  The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito Vector , 2012, Antimicrobial Agents and Chemotherapy.

[37]  E. Beutler,et al.  The hemolytic effect of primaquine and related compounds: a review. , 1959, Blood.

[38]  O. Gaye,et al.  Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial , 2010, The Lancet.

[39]  David M. Shackleford,et al.  Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. , 2011, Journal of medicinal chemistry.

[40]  E. Winzeler,et al.  The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites , 2012, PLoS medicine.

[41]  J. Lelièvre,et al.  Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence “Transmission Blocking” Assay , 2012, Malaria Journal.

[42]  K. Kuhen,et al.  Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents , 2011, Journal of medicinal chemistry.

[43]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[44]  Ana Rodriguez,et al.  The silent path to thousands of merozoites: the Plasmodium liver stage , 2006, Nature Reviews Microbiology.

[45]  Guoli Zhou,et al.  Wolbachia Invades Anopheles stephensi Populations and Induces Refractoriness to Plasmodium Infection , 2013, Science.

[46]  Félix Calderón,et al.  A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold. , 2012, ACS medicinal chemistry letters.

[47]  Peter G. Schultz,et al.  A Chemical Genomic Analysis of Decoquinate, a Plasmodium falciparum Cytochrome b Inhibitor , 2011, ACS chemical biology.

[48]  D. Koop,et al.  Optimization of endochin-like quinolones for antimalarial activity. , 2011, Experimental parasitology.

[49]  A. Janowsky,et al.  Discovery of dual function acridones as a new antimalarial chemotype , 2009, Nature.

[50]  Bruce Russell,et al.  Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription , 2011, BMC Genomics.

[51]  J. Stockman First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .

[52]  M. Mota,et al.  The Next Opportunity in Anti-Malaria Drug Discovery: The Liver Stage , 2011, PLoS pathogens.

[53]  Yongyuth Yuthavong,et al.  Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target , 2012, Proceedings of the National Academy of Sciences.

[54]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[55]  J. Kevin Baird,et al.  Resistance to Therapies for Infection by Plasmodium vivax , 2009, Clinical Microbiology Reviews.

[56]  Elizabeth A. Winzeler,et al.  Na+ Regulation in the Malaria Parasite Plasmodiumfalciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials , 2013, Cell host & microbe.

[57]  Anang A. Shelat,et al.  Chemical genetics of Plasmodium falciparum , 2010, Nature.

[58]  David M. Shackleford,et al.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. , 2009, Journal of medicinal chemistry.

[59]  Cécilie Martin,et al.  Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug , 2012, The Journal of infectious diseases.

[60]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[61]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[62]  W. Milhous,et al.  The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. , 1993, Annals of tropical medicine and parasitology.

[63]  Kami Kim,et al.  Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites. , 2009, The Journal of infectious diseases.

[64]  V. Avery,et al.  Whole-cell in vitro screening for gametocytocidal compounds. , 2012, Future medicinal chemistry.

[65]  Miguel Prudêncio,et al.  Liver-stage malaria parasites vulnerable to diverse chemical scaffolds , 2012, Proceedings of the National Academy of Sciences.

[66]  Christian Scheurer,et al.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.

[67]  Trixie Wagner,et al.  Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria , 2010, Journal of medicinal chemistry.

[68]  Bradley I. Coleman,et al.  Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model* , 2010, The Journal of Biological Chemistry.

[69]  M. Dixon,et al.  Sex in Plasmodium: a sign of commitment. , 2008, Trends in parasitology.

[70]  Choukri Ben Mamoun,et al.  Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission , 2013, Proceedings of the National Academy of Sciences.

[71]  P. Wilairat,et al.  Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening , 2004, Antimicrobial Agents and Chemotherapy.

[72]  P. Newton,et al.  A Major Genome Region Underlying Artemisinin Resistance in Malaria , 2012, Science.

[73]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[74]  D. Diallo,et al.  Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications. , 2010, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[75]  Bradley I. Coleman,et al.  Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. , 2011, Chemistry & biology.

[76]  Balbir Singh,et al.  Human Infections and Detection of Plasmodium knowlesi , 2013, Clinical Microbiology Reviews.

[77]  Francisco-Javier Gamo,et al.  Global phenotypic screening for antimalarials. , 2012, Chemistry & biology.

[78]  Richard J Sciotti,et al.  CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine , 2012, Malaria Journal.

[79]  K. Rieckmann,et al.  Simple In Vitro Assay for Determining the Sensitivity of Plasmodium vivax Isolates from Fresh Human Blood to Antimalarials in Areas where P. vivax Is Endemic , 2003, Antimicrobial Agents and Chemotherapy.

[80]  G. Evans,et al.  Plasmodium falciparum Parasites Are Killed by a Transition State Analogue of Purine Nucleoside Phosphorylase in a Primate Animal Model , 2011, PloS one.

[81]  P. Olliaro,et al.  The Global Portfolio of New Antimalarial Medicines Under Development , 2009, Clinical pharmacology and therapeutics.

[82]  R. Sauerwein,et al.  A Plant-Derived Morphinan as a Novel Lead Compound Active against Malaria Liver Stages , 2006, PLoS medicine.

[83]  J. Burrows,et al.  The global pipeline of new medicines for the control and elimination of malaria , 2012, Malaria Journal.

[84]  K. Williamson,et al.  A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. , 2011, Molecular and biochemical parasitology.

[85]  M. Fay,et al.  Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays , 2013, PloS one.

[86]  Gilean McVean,et al.  Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia , 2013, Nature Genetics.

[87]  R. Sinden,et al.  A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. , 2012, International journal for parasitology.

[88]  Marcel Tanner,et al.  Malaria eradication back on the table. , 2008, Bulletin of the World Health Organization.

[89]  M. Mota,et al.  Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins , 2013, Proceedings of the National Academy of Sciences.

[90]  M. Tanner,et al.  The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. , 2002, The American journal of tropical medicine and hygiene.

[91]  P. Rathod,et al.  Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. , 1982, Molecular and biochemical parasitology.

[92]  C. Rogier,et al.  The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. , 2011, ACS chemical biology.

[93]  Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa , 2013, Malaria Journal.

[94]  V. Yardley,et al.  Antiparasitic Activities and Toxicities of Individual Enantiomers of the 8-Aminoquinoline 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-Dichlorophenoxy]Quinoline Succinate , 2008, Antimicrobial Agents and Chemotherapy.

[95]  C. Harris,et al.  The Design and Application of Target-Focused Compound Libraries , 2011, Combinatorial chemistry & high throughput screening.

[96]  K. Kain,et al.  Tafenoquine: a promising new antimalarial agent , 2007, Expert opinion on investigational drugs.

[97]  K. Cimanga,et al.  Antimalarial Efficacy of a Quantified Extract of Nauclea pobeguinii Stem Bark in Human Adult Volunteers with Diagnosed Uncomplicated falciparum Malaria. Part 2: A Clinical Phase IIB Trial , 2012, Planta Medica.

[98]  R. Sinden,et al.  Assessing transmission blockade in Plasmodium spp. , 2013, Methods in molecular biology.

[99]  Bruce Russell,et al.  Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.

[100]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[101]  A. Thomas,et al.  Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.

[102]  Kwaku Poku Asante,et al.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.

[103]  José María Bueno,et al.  An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. , 2011, ACS medicinal chemistry letters.

[104]  D. Wirth,et al.  Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2008, Journal of Biological Chemistry.

[105]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[106]  Peter G. Schultz,et al.  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.

[107]  David M. Shackleford,et al.  3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. , 2012, Journal of medicinal chemistry.

[108]  K. Kuhen,et al.  Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial Agents , 2012, Journal of medicinal chemistry.

[109]  J. Chollet,et al.  Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. , 2013, Journal of medicinal chemistry.

[110]  John A. Tallarico,et al.  Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin , 2012, Cell host & microbe.

[111]  Leann Tilley,et al.  Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion , 2011, Proceedings of the National Academy of Sciences.

[112]  Jeremy N. Burrows,et al.  Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen , 2011, Antimicrobial Agents and Chemotherapy.

[113]  Simon J F Macdonald,et al.  Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). , 2011, ACS medicinal chemistry letters.

[114]  Nancy Fullman,et al.  Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.

[115]  William J. Welsh,et al.  Structure-based Design of Novel Small-Molecule Inhibitors of Plasmodium falciparum , 2010, J. Chem. Inf. Model..

[116]  Yu Wang,et al.  Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. , 2011, Molecular and biochemical parasitology.

[117]  V. Avery,et al.  Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening , 2012, The American journal of tropical medicine and hygiene.

[118]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[119]  S. Puri,et al.  Inhibition of the development of the hepatic stages of Plasmodium yoelii nigeriensis by antihistaminic agents. , 1999, Annals of tropical medicine and parasitology.

[120]  Ogobara K. Doumbo,et al.  A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.

[121]  L. H. Schmidt Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys , 1983, Antimicrobial Agents and Chemotherapy.

[122]  F. Muregi,et al.  Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design , 2009, Drug development research.

[123]  A. Vaughan,et al.  That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda , 2010, Science.

[124]  D. Warhurst,et al.  The chemotherapy of rodent malaria. XLIV. Studies on the mode of action of CM 6606, an indolo (3,2-c) quinoline N-oxide. , 1989, Annals of tropical medicine and parasitology.

[125]  T. Spicer,et al.  A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes. , 2011, Molecular and biochemical parasitology.

[126]  R. Moreira,et al.  Primaquine revisited six decades after its discovery. , 2009, European journal of medicinal chemistry.

[127]  Caroline W. Kabaria,et al.  The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009 , 2010, PLoS neglected tropical diseases.

[128]  Yuexin Li,et al.  Quinolone-3-Diarylethers: A New Class of Antimalarial Drug , 2013, Science Translational Medicine.